CDK6 and neoplasm: Resistance to CDK4/6 inhibition is characterized by loss of tumor suppressors such as RB and FAT1. Notably, loss-of-function mutations of FAT1, a Hippo pathway receptor, are observed in 2% and 6% of primary and metastatic tumors, respectively, and result in increased CDK6 expression due to the recruitment of YAP and TAZ to the CDK6 promoter to drive G1/S progression74.